Calidi Biotherapeutics Inc. (CLDI) — Cash Flow-to-Debt Ratio

Latest as of December 2025: -0.99x

Calidi Biotherapeutics Inc. (CLDI) has a Cash Flow-to-Debt Ratio of -0.99x as of December 2025, meaning its operating cash flow of $-5.04 Million could theoretically repay -1% of its total liabilities ($5.10 Million) in one year. See how liquid is Calidi Biotherapeutics Inc.'s working capital to evaluate short-term liquidity relative to the company's equity base.

CF-to-Debt Ratio

-0.99x
Operating CF / Total Liabilities

Operating Cash Flow

$-5.04 Million
USD

Total Liabilities

$5.10 Million
USD

Data as of

Dec 2025
Most recent filing

Calidi Biotherapeutics Inc. Cash Flow-to-Debt Ratio (2020–2025)

Historical debt coverage capacity for Calidi Biotherapeutics Inc. across 6 annual periods. Also explore net asset growth rate of Calidi Biotherapeutics Inc. to track the company's year-over-year net asset growth rate.

Annual Cash Flow-to-Debt Ratio for Calidi Biotherapeutics Inc. (2020–2025)

Year-by-year debt coverage analysis for Calidi Biotherapeutics Inc.. For market capitalisation and broader financial context, see Calidi Biotherapeutics Inc. (CLDI) market capitalisation.

Year CF-to-Debt Ratio Operating CF (USD) Total Liabilities YoY Change
2025 -4.18x $-21.29 Million $5.10 Million ▼ -159.0%
2024 -1.61x $-19.69 Million $12.21 Million ▼ -9.1%
2023 -1.48x $-26.98 Million $18.25 Million ▼ -493.3%
2022 -0.25x $-13.21 Million $53.04 Million ▲ +16.7%
2021 -0.30x $-7.77 Million $26.00 Million ▼ -50.7%
2020 -0.20x $-4.83 Million $24.33 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.